Manolete FY26 slides: record £67m forward book offsets earnings dip

Manolete reported FY26 realised revenue of £27.9 million, down 6% year over year, but gross profit rose 8% to £10.4 million and gross margin expanded to 37% from 32% as the company shifted toward larger, higher-margin claims. Results were weighed down by a £1.8 million specific bad debt provision and adjusted realised PBT of just £0.1 million, though management said it would have been £1.9 million excluding the provision and highlighted a record £67 million forward book. The company also set medium-term targets for 50% revenue growth to £42 million and positive net cashflow, while shares rose 1.33% on the update.

Analysis

The key signal is not the headline miss; it’s the composition shift toward larger claims, which should mechanically lift returns on deployed capital if execution holds. In this model, a modest increase in average case value can compound meaningfully because overhead is largely fixed and collection velocity matters more than top-line volume. The market is still discounting the stock as if it were a cyclical earnings story, when the real re-rating trigger is proof that the forward book can convert into cash with better margin and lower case-count dependence.

The near-term overhang is working-capital volatility, not franchise impairment. A small number of delayed debtor payments can swamp reported profitability in any given year, but that also means the stock should respond sharply to a single clean collections quarter or evidence that the specific provisions are reversing. The balance-sheet constraint is real: management is prioritizing solvency over buybacks, which is sensible, but it also delays the fastest equity-supportive use of cash until leverage bends down.

The market may be missing second-order competitive effects from the pivot upmarket. Larger claims are harder for smaller funders to underwrite and service, which should improve Manolete’s share of the more attractive segment and widen the gap in case quality over time. If the pipeline continues to skew higher value, the relevant comparison is not current earnings but future ROIC on incremental capital; that makes the medium-term guide the real catalyst, not this year’s provision noise.

Contrarian risk: the stock can look optically cheap for longer than expected if collections remain lumpy, and any additional debtor slippage would undermine confidence in the forward book. But if the next 1-2 quarters show normalization in receipts and case completion mix, the combination of margin expansion, higher average case value, and low market share leaves room for a sharp rerating rather than a gradual one.

Key Decisions for Investors

• Long MANO on weakness, 3-6 month horizon: accumulate into any post-results drift below book-adjacent valuations; upside is a rerating toward a higher-quality legal asset comp if collections normalize, with downside anchored by tangible NAV and a growing forward book.
• Buy MANO call spreads 6-12 months out: structure around the medium-term target cadence rather than near-term earnings; this is a clean way to express upside from one or two clean collection quarters without taking full balance-sheet risk.
• Pair trade: long MANO / short a lower-quality litigation or special-situations lender if available in the listed universe; thesis is that larger-case mix and in-house execution should outperform lenders more exposed to smaller, noisier claims.
• Avoid adding before the next collections update if you need clean catalysts: the stock is vulnerable to another debtor headline in the next 1-2 months, which would likely delay any re-rating despite underlying pipeline strength.
• If you hold the name, use a staged add-on after confirmation of improved debtor conversion; the best risk/reward comes from buying when reported cash receipts catch up to the forward book, not when sentiment first turns.